immortal cell line cell 永生细胞系细胞 NICR277 cell NICR277 细胞 1. Cell Resource Center of Peking Union Medical College provides experimental cell technology services for scientific research. The provided experimental cells and their offspring can not be used in human experiments and clinical diagnosis and treatment, and can not be used for commercial activities directly or indirectly. 2. Cell Resource Center of Peking Union Medical College is committed to doing its utmost to update experimental cell resources in a timely fashion. But limited to the technical conditions at the time, the center does not guarantee its accuracy. 3. The Center did not verify information cited from the literature, etc, for reference purposes only. 4. Users should observe the relevant laws and regulations at home and abroad when receiving, handling, preserving, discarding, transferring and using cells, taking into account the risks and liabilities that may exist and taking appropriate safety and handling measures to minimize hazards to health or the environment. 3111C0001CCC000277 Amelogenin：X；CSF1PO：12；D13S317：8，11；D16S539：11，13；D18S51：14，19；D19S433：13；D21S11：29，30；D2S1338：23，24；D3S1358：15，17；D5S818：10；D7S820：9，11；D8S1179：14，15；FGA：22，24.2；TH01：7，9；TPOX：8；vWA：14，17； Base Medium+8%DMSO+20%FBS Cell Culture Center, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences Class A Culture Method（-） HCC 94 HCC 94 cell HCC-94 HCC-94 cell HCC-94-cell morphology-PUMC HCC941122 HCC941122 cell Human Uterine Squamous Carcinoma Cells (Highly Differentiated); HCC-94 [HCC941122; HCC 94] It was established in 1995, the 2nd generation tumor tissue for nude mice xenografts HCC94V of human cervical highly differentiated squamous cell carcinoma, was in sticking cultivation and began to grow after 6 days, and the first passage was of 112 days, and it was transplanted subcutaneously to the BALB/c-nu/nu nude mice and formed tumors. NICR277 Passage at 1: 3 ~ 1: 4, and passage once in 2 to 3 days. RPMI 1640 (w/o Hepes) 10%FBS Unknown Zhenli Yang, Yuqin Liu, Tel:65286441, 69156455, Email:crcpumc@vip.163.com adherent growth epithelioid http://www.cellresource.cn/fdetail.aspx?id=277 http://www.cellresource.cn/pdf/20080108101040.pdf 1. 协和细胞资源中心为科学研究提供实验细胞技术服务。所提供的实验细胞及其子代，不能用于人体实验和临床诊断、治疗，不能直接或间接用于商业行为。 2. 协和细胞资源中心承诺尽最大努力对实验细胞资源相关信息进行及时更新。但限于当时的技术条件，中心不保证其准确性。 3. 从文献等处引用的信息本中心未进行核实，仅供参考。 4. 使用者在接收、处理、保存、丢弃、转让及使用细胞的时候要遵守国内外有关的法律法规，充分考虑可能存在的风险和责任，采取适当的安全和处理措施尽量降低对健康或环境的危害 1995年建系，人宫颈高分化鳞癌裸小鼠移植瘤HCC94V第2代瘤组织，贴壁培养，6日细胞开始生长，首次传代38日，BALB/c-nu/nu裸小鼠皮下移植成瘤。 1:3~1:4传代，2~3天1次。 Amelogenin：X；CSF1PO：12；D13S317：8，11；D16S539：11，13；D18S51：14，19；D19S433：13；D21S11：29，30；D2S1338：23，24；D3S1358：15，17；D5S818：10；D7S820：9，11；D8S1179：14，15；FGA：22，24.2；TH01：7，9；TPOX：8；vWA：14，17； A类 HCC 94 细胞 HCC-94 细胞 HCC-94-细胞形态-PUMC HCC941122 细胞 RPMI 1640 (w/o Hepes) 10%FBS http://www.cellresource.cn/pdf/20080108101040.pdf 上皮样 不详 中国医学科学院基础医学研究所基础医学细胞中心 人子宫鳞癌细胞（高分化）；HCC-94 [HCC941122；HCC 94] 培养法（-） 基础培养基+8%DMSO+20%FBS 杨振丽，刘玉琴，Tel:65286441，69156455；Email:crcpumc@vip.163.com 贴壁生长